2-氯-1-甲基-1H-苯并咪唑 | 1849-02-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-氯-1-甲基-1H-苯并咪唑
• 中文别名: 2-氯-1-甲基-(9ci)-1H-苯并咪唑
• 英文名称: 2-chloro-1-methyl-benzimidazole
• 英文别名: 2-chloro-1-methyl-1H-benzo[d]imidazole；2-chloro-1-methyl-1H-benzimidazole；2-chloro-1-methyl-1H-benzoimidazole；2-chloro-N-methylbenzimidazole；N-methyl-2-chlorobenzimidazole；1-methyl-2-chlorobenzimidazole；2-chloro-1-methylbenzimidazole
• CAS: 1849-02-1
• 化学式: C₈H₇ClN₂
• mdl: MFCD00769821
• 分子量: 166.61
• InChiKey: UXZYKSFMGDWHGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  117-117.5 °C(Solv: ligroine (8032-32-4))
• 沸点：
  303.4±25.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P304+P340,P305+P351+P338,P405
• 危险性描述：
  H315,H319,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Chloro-1-methyl-1,3-benzodiazole
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Chloro-1-methyl-1,3-benzodiazole
Ingredient name:
CAS number: 1849-02-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7ClN2
Molecular weight: 166.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-1-甲基-1H-苯并咪唑 以 aqueous HOAc 、 N,N'-二甲基乙二胺 为溶剂， 以5.39 g (82%)的产率得到2-amino>-1-methyl-1H-benzimidazole
  参考文献：
  名称：

  Substituted arylsulfonamides and benzamides

  摘要：

  这项发明涉及具有抗心律失常活性的取代芳基磺胺和苯甲酰胺，以及制备这些化合物的药物组合物和方法。

  公开号：

  US05149700A1
• 作为产物：
  描述：

  N-甲基咪唑 在 四氯化碳 、 sodium t-butanolate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以51%的产率得到2-氯-1-甲基-1H-苯并咪唑
  参考文献：
  名称：

  一种制备卤代(杂)芳烃的方法

  摘要：

  本发明涉及一种制备卤代(杂)芳烃的方法。以廉价易得的全氟碘代丁烷、四溴化碳和四氯化碳分别作为碘代、溴代和氯代试剂，在碱催化(促进)作用下，制备卤代(杂)芳烃。该方法步骤如下：首先，将(杂)芳烃，卤代试剂和无机碱置于有机溶剂中，室温下搅拌，TLC监测直至底物消失，停止反应。然后，将反应混合液倒入水中，萃取，有机相干燥，减压除去有机溶剂。最后，将粗产物进行硅胶柱层析，得到产物。也可通过重结晶方法提纯。本发明合成路线具有底物范围宽、原料和试剂廉价易得、操作简单、条件温和、产率高、节约能耗、反应路线安全和可克级制备等优点。

  公开号：

  CN107501023B

文献信息

• Pyridinium betaines derived from thiazolo and imidazoacridinones
  作者：Jean-Pierre Galy、Jean-Pierre Hanoun、Valerie Pique、Nadine Jagerovic、JosÉ Elguero

  DOI：10.1002/jhet.5570340623

  日期：1997.11

  Four betaines derived from imidazo[4,5-a], imidazo[5,4-a] and thiazolo[5,4-a]acridine have been prepared in a six step procedure starting from 2-chlorobenzimidazoles and benzothiazoles. The 1H and 13C nmr has been used to characterize the compounds, particularly the orientation of the step leading to the formation of the acridinone ring. The uv-visible spectra of one betaine (wave numbers v in cm−1)

  从咪唑并[4,5衍生四甜菜碱一个]，咪唑并[5,4-一个]和噻唑并[5,4-一个]吖已经从2- chlorobenzimidazoles和苯并噻唑开始的6个步骤过程中被制备。的1 H和13 C NMR被用于表征化合物中，步骤导致吖啶酮环的形成特别的方位。一个甜菜碱的紫外-可见光谱（波数v在cm -1中）显示出与Reichardt的E T参数呈线性关系，并且对溶剂效应具有很高的敏感性。
• LTA4H modulators and uses thereof
  申请人：Barchuk William T.

  公开号：US20080194630A1

  公开（公告）日：2008-08-14

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  白三烯A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的方法。
• 2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity
  作者：Lei Wang、Marina Kofler、Gerald Brosch、Jelena Melesina、Wolfgang Sippl、Elisabeth D. Martinez、Johnny Easmon

  DOI：10.1371/journal.pone.0134556

  日期：——

  e ring was replaced by the isosteric heterocycles benzimidazole, benzoxazole, and benzothiazole and the position of the hydroxamic acid substituent on the phenyl ring was varied. Whereas compounds bearing a para substituted hydroxamic acid (9a-d) were active HDAC inhibitors, the meta substituted analogues (8a-d) were appreciably inactive. Compounds 9a-d selectively inhibited HDAC6 (IC50 = 0.1-1.0 μM)

  我们已经在建立的基于细胞的测定法中筛选了我们的化合物集合，该测定法测量表观遗传沉默的转基因的去阻抑，即基因座去阻抑测定。该筛选导致鉴定出4- [4-（1-（甲基苯并咪唑-2-基）哌嗪-1-基]磺酰基苯碳氧肟酸（9b）作为抑制HDAC1的活性物质。在初始结构活性关系研究中，1-甲基苯并咪唑环被等位杂环苯并咪唑，苯并恶唑和苯并噻唑取代，并且异羟肟酸取代基在苯环上的位置也有所变化。带有对位取代的异羟肟酸（9a-d）的化合物是活性HDAC抑制剂，而间位取代的类似物（8a-d）则无活性。与HDAC1（IC50 = 0）相比，化合物9a-d选择性抑制HDAC6（IC50 = 0.1-1.0μM）。而且，与患者匹配的正常细胞相比，也有选择性地抑制了肺癌细胞（9-6μM）的生长。与对照组相比，该化合物在S期诱导细胞周期停滞，而细胞凋亡的诱导则可忽略。分子模型研究发现，9a-d与HDAC6相互作用的MM-G
• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• Synthesis of novel substituted 3-(4-((1H-benzo[d]imidazol-2-ylthio)methyl)-1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-ones: various approaches
  作者：Devulapally Srikrishna、Pramod Kumar Dubey

  DOI：10.1007/s11164-018-3397-x

  日期：2018.7

  a privileged structure for developing probes of impressive pharmacological potentials, some new coumarin and pyrazole conjugates of benzimidazoles were synthesized with a sulphur linkage. Thus, 3-(2-oxo-2 H -chromen-3-yl)-1-phenyl-1 H -pyrazole-4-carbaldehyde ( 3 ) was prepared starting from simple salicylaldehyde which has been used as an important synthon and incorporated in a series of structural

  摘要以 苯并咪唑为优先结构，可开发出令人印象深刻的药理潜力的探针，合成了一些新的具有硫键的苯并咪唑香豆素和吡唑共轭物。因此，3-（2-氧代-2- ħ -苯并吡喃-3-基）-1-苯基-1- ħ 吡唑-4-甲醛（ 3 ）的制备从已经作为重要的合成子和并入简单水杨醛开始在一系列结构操作中获得各种药效基序缀合物 9（a–b） 和 13（a–f） ，以合理的收益率。我们已经开发出了简便且逐步的方法，可以通过各种方法合成所有这些化合物，其中还涉及子序列。通过IR，1 HNMR，13 CNMR和质谱数据很好地表征了所有合成的化合物。 图形概要